CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.78% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Verona Pharma PLC (NASDAQ: VRNA) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma. Its lead candidate, ensifentrine, is designed to improve lung function and reduce symptoms for patients with chronic respiratory conditions. By combining breakthrough science with a patient-centric approach, Verona Pharma aims to bring next-generation treatments to the global respiratory market.
Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.